Advertisements
Feeds:
Posts
Comments

Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

On May 24, 2018

Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 –About my doctoral advisor, Allan Pred, other Professors and other Peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

 

Part 2 places an emphasis on my feelings as time had passed by and I was looking back in time.

I describe my eventful five years at Berkeley, 9/1978 – 12/1983, as a walk on a steep uphill trail, simulating a climb on Mount Rainier. Why this mountain?

My arrival to California and enrollment at Berkeley was equivalent to climbing the highest mountain in the PNW. 

My arrival in the San Francisco Bay Area was like approaching a cultural stratovolcano, and the Californian landscape I traversed on my daily rides was like a daily visit to a national park along highway 280 between Palo Alto and San Francisco at 8:30AM and 5:30PM

The Gutenberg Express bus service between Stanford and UC, Berkeley would drop me off at Doe Memorial Library and I would climb the campus path to McCone Hall or to the I-House on Piedmont Avenue.

Some days, I would arrive with BART to Berkeley and use the Bogart Shuttle to the West Gate.

Berkeley Campus Architecture, Image Source: Google Images

At Berkeley I walked uphill from Moffit Hall to Cory Hall when I taught a Quantitative Methods upper division course three trimesters in two academic years. I walked northeast from Giannini Hall to Wurster Hall at the South Gate or from Crescent/Springer Gateway at the West Gate to the Health Services building, which was located where today the Haas School of Business is located on the southeast corner of the campus.  

While the walking paths were the most magnificent arboretum design of any campus in the US and the topography seemed most pleasantly hilly (288 m to 860 m), the elevation felt like “climbing” a prominent mountain, in my mind, Mount Rainier.

Trees of Berkeley. Slide show with photos and identification of several notable trees on campus.

SOURCE: http://guides.lib.berkeley.edu/campus_research/landscape 

 

Like Mount Rainier in my Doctoral Dissertation, filed 12/1983, titled “Corporate Growth and Locational Interdependence: Observations on the Production, Location, Merger Activity and Organizational Structure of American Paper Companies.”

 

Mount Rainier, Image Source: Google Images

 

I researched, the Pacific Northwest timber industry, the hemlock evergreen tree used for its pulpwood by the paper industry, studying its production and location. The world’s leading paper company, International Paper (IP) Co’s timberland holdings in the Mount Rainier region are included in one of the chapters. This material was extracted from IP’s Corporate Annual Reports, 1901-1975, located in the stacks of the Graduate School of Business (GSB) at Stanford University in the summers of 1980 and 1981, when I was in an exchange program between UCB and Stanford’s GSB.

 

As a memorium to my mentors, I describe the interactions and the lasting impact they had on my professional life. It was a way to compose their eulogies as an autobiographical account of professor – graduate student relationships.

 

“While Enrolling”

Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley

Edit

http://oldweb.geog.berkeley.edu/PeopleHistory/faculty/AllanPred_InMemoriam.html#A%20reflection%20by%20Aviva%20Lev-Ari

January 2007

The sudden and most untimely death of Prof. Allan Pred, my doctoral advisor, 1978-1983, was both an unexpected event and very shocking and unbelievable news to every doctoral student Allan had, to our department, our discipline and academic sciences fields in the US and the world.

A giant of unprecedented proportions is gone. His legacy is eternal.

I was stunned and couldn’t believe the cause of death: lung cancer. Allan never smoked, biked up hill every day six month of every year, was slimmer than most of us, enjoyed lunch more than most of us and was engaged intensely in research and writing a rather solitary activity which caused him much pleasure. This was not a stressful activity since he was a great writer, most prolific, published in quality and quantity unmatched proportions compared to most other faculty at UC Berkeley. Thus he was not under pressure from the administration. He joined UC in 1962 at 26 years old and was tenured before he was 30 years old!! No publisher ever rejected his books or requested fundamental changes to his writings.

We are all mortals. How can anyone predict the risk of dying based on life style? Allan, the healthiest of all, died at the age of 70 (1936-2007) from lung cancer as a non-smoker. For Allan no modification to his activities of daily living was recommended!!

Who was Allan to me since 9/1978 and before? A mentor, a teacher, a friend, a well-wisher, a source of encouragement, a critic, a standard setter, and a source of over thirty years of inspiration which started with reading his Location and Behavior (1967), while I was a Masters student in urban planning at The Hebrew University in Jerusalem, Israel, 1973 – 1976.

During these three years, I was a student of Prof. Barry Kibel, who got his PhD in the City Planning Department at UC Berkeley under Prof. Michael Tietz in Planning and Allan Pred in Geography. Prof. Kibel encouraged me to apply to UC Berkeley and explore working with Allan Pred. Kibel’s recommendation letter was a determining factor in my initial contact with Allan Pred in 1978.

I was very fond of Allan, wrote poetry for him as I corrected the draft of my doctoral thesis because of the intense inspiration he provided and the challenging comments he made on my writings. I knew that nothing but very exceptional would be approved, needless to say signed. Allan’s breath of interests included organizational behavior economics. This enabled me to work on a topic which was very interdisciplinary in nature and to combine location theory with this area in economics, which took off later, in the late 80s and 90s, chiefly through the work of Prof. Paul Krugman, an entire decade after my thesis was completed.

Prior to my graduation from Berkeley, I worked in several academic institutions: at HUJI, as RA and TA, four years. At Technion – IIT, as research associate, two years. At UCB, as TA, two years.

Allan’s guidance during my graduate studies at Berkeley yielded a body of research which facilitated my 20 year career in the “for-profit” sector in key industries such as top tier management consulting (SRI, Int’l), computer hardware and software (Amdahl Corp), federal funded research and development (MITRE) and publishing (McGraw-Hill). Allan’s most impact was on my positions in the top tier management consulting industry: Stanford Research Institute (SRI) Int’l in Menlo Park, and the Monitor Group in Cambridge, MA, to where I moved in 1990. Allan suggested that I inquire about opportunities at Arthur D. Little in Cambridge, MA; he knew all about the management consulting field.

At SRI, my dissertation under Allan Pred was viewed as a readymade body of theory that I could apply to their clients in mature industries requiring new conceptualization for revitalization of otherwise stagnant sectors of the economy. It was in the mid 80’s when the chemical and automotive industries needed a new strategy. My thesis at Berkeley under Allan Pred could provide consulting for SRI clients such as General Motors, DuPont, Alcan, and Phone-Poulenc, as I did till late 1988 when I joined Amdahl Corporation in Sunnyvale, CA.

Without him, I would not have had the confidence to get my first job in the US at the Stanford Research Institute in 1984, where I held the director title at age 35. I knew I had Allan’s blessing and that should I need to build another theoretical model, he would accept my phone call from Menlo Park and continue to instruct me. Without him, I might not have received the three teaching assistantships which covered my tuition as a non-California resident for the first three years at UC Berkeley. Without him, my admission to the University of Chicago (his own alma mater) might not have been transferred or transferable to UC Berkeley.

Allan gave me my first chance in the US, and following graduation from Berkeley, I took off to conduct applied research in corporate America. The twenty years I worked in this field, yielded over sixty technical reports and over 200 invited lectures. Allan knew the details and told me that my career demonstrated the viability of our discipline outside of academe. I had the opportunity to share with him these facts and discuss their impact on corporate decision making.

I met him for the last time in 2000 in San Francisco in the lobby of the Museum Of Modern Art, and we walked together to an exhibition in architecture by the most gifted woman architect in the 20th century, Ms. Zaha Haddid. Having the chance to look at her exhibit in his company and experience many moments when both of us were in awe at her ingenuity made this SF visit the most special afternoon in my entire life. We looked at each other with complete admiration for her accomplishments in computer graphics and concept modeling. He told me, “I planned to go to her exhibit, I am glad, because of you and with you I am here in San Francisco today.” We continued to another exhibit on the upper floor on Wired magazine since its inception. Allan told me that he likes to browse there once in a while, though he does not do it often enough. Having a chance to look together at the first five issues, issued in the early 80s, caused him great joy.

We had an hour of talking over his favorite cappuccino with all the trimmings in the museum cafeteria. He was smiling constantly, asking questions, and continuing professor-graduate student relations as if twenty years had not gone by. We parted with his bear hug and few e-mails since. In May 2002 when I arrived in Monterey, CA, I e-mailed him to say that he is invited to visit. He said, “another time, since I am leaving to Sweden in one week, after I’ll return to Berkeley by mid of August 2002.”

I met Allan at the memorial for Prof. Vance, the centennial to the department, and on a talk I gave at the Haas School of Business in 2001 when he came to listen. In 2002/2003, while living in Monterey on an assignment for McGraw-Hill, I visited the campus and gave a talk at Berkeley’s Center for Globalization and Information Technology, where I meet Dick Walker, who was a discussant, but missed Allan who was on sabbatical.

I planned to share with Allan my new research on biomarkers for cardiovascular disease, in particular a forthcoming paper in American Journal of Cardiovascular Drugs. I waited to have it published to let Allan know. Now it is too late to share.

Allan, was a person who, once you knew, you knew you were not going to ever forget. For myself and his other doctoral students, Allan remains vivid in memory, eternal like the memory of a much loved parent.

Aviva Lev-Ari, PhD ’83

http://oldweb.geog.berkeley.edu/PeopleHistory/faculty/AllanPred_InMemoriam.html#A%20reflection%20by%20Aviva%20Lev-Ari

 

Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley

Edit

http://oldweb.geog.berkeley.edu/PeopleHistory/faculty/HoosonMemorial/DavidHooson_Memories.html

2008

I am very sad to learn about another great loss to humanity, to academia, to UC Berkeley, and to human geography.

David Hooson had probably the greatest generosity of spirit I have encountered in my life.

His courses were a 360 degree vista of human ecology with the finest sensitivity to the human condition paralleled only by that in Bernard Q. Nietschmann’s courses at Berkeley.

David Hooson will always have a special place in my heart for being most kind to me in several critical junctions in my career: (a) the admission to the doctoral program in the department, (b) while I was a doctoral student at UC Berkeley, 1978-1983, as an international student in his courses, in need of TLC while facing the unfamiliar academic landscape at UCB (c) meeting with me when my doctoral advisor, Prof. Allan Pred was on Sabbatical and I was writing my thesis, (d) his warm greetings at the end of the graduation ceremony, 5/1983, when I held my 18 month old son in my arms and he said to me, “Aviva, you are the only PhD we had to have a baby while a doctoral student, and to graduate in five years, while our average used to be 7 1/4 years” (e) a lengthy conversation during an open house weekend in the department in the late 80s, (f) a conversation during the memorial to James E. Vance, Jr., (g) a conversation at a memorial lecture to Professor Carl O. Sauer, and on our last meeting at the centennial celebration of the department.

David Hooson and no other man, has let me feel that he offered his undivided attention to me. In our interactions, he offered as much time it took to complete an intellectual exchange.

To Prof. Hooson’s family, I say that his legacy as a humanist will remain in the minds of all his colleagues and all his students — a touching smile just to comfort the other’s heart. He put so many at peace with themselves.

Aviva Lev-Ari, PhD’83

http://oldweb.geog.berkeley.edu/PeopleHistory/faculty/HoosonMemorial/DavidHooson_Memories.html

 

“While Rolling”

When Prof. Allan Pred was on sabbatical, 1980 – 1983, Prof. Michael Watts served as my acting advisor.

On May 13, 2018, I wrote:

Dear Prof. Watts,

I remember you so very fondly. You put me at ease while the competition among the peers was fierce. I had deficits in English language, American culture, and the Berkeley campus-specific cultural ecology. I had to learn the ropes fast!! [Some I did not get right then, and even today I make some mistakes.]

It was providence that aligned Prof. Allan Pred to hover over my Berkeley existence.

If he were alive, he would have become familiar with my professional activities, after 2007, the 3rd and 4th phases. He praised me for getting the job at SRI International. Prof. Pred had attended two talks I gave at Berkeley over the years, one organized by Prof. Arie Segev at the Haas School of Business, and the second and third talks arranged by Prof. Michel Laguerre at the Center for Globalization and Information Technology. Allan knew that I took the job at McGraw-Hill in Monterey, CA while he was on sabbatical. We even discussed his potential visit to Monterey upon his return from Sweden, August 2002, although the time was left open.

I believe that Professor Pred would have said that a professional is judged by “his or her’s contributions to science, society, making the world a better place for others and the pursuit of happiness.” His work was interdisciplinary in nature, and I have pursued the interface between disciplines since my Masters thesis at the Hebrew University in Jerusalem, 1973-1976. In 25 years of working in corporate America for companies that are #1 in their sector, i.e.: I received and accepted eleven job offers!

Chiefly,

  • SRI International, Menlo Park, CA – Largest THINK TANK in the US [My Title: Director Business & Economic Statistics]
  • Amdahl Corporation, Sunnyvale, CA  – 3rd largest Main Frame Computer company in the World, acquired by Fujitzu [My Title: Manager, Demand Forecasting and Modeling]
  • Monitor Group, Cambridge, MA – Top Tier Management Consulting, acquired by Deloitte [Senior Methodology Consultant, Financial Sector]
  • MITRE, Bedford, MA – Largest Federal Funded R&D Corporation [My Title: Head of Research, Economic & Decision Analysis Center]
  • Perot Systems Corporation, Cambridge, MA – Top IT Outsourcer, acquired by Dell Computers [My Title: Director, Advance Analytics Digital Marketplaces]
  • McGraw-Hill/CTB, Monterey, CA – World Oldest Publisher [My Title: Director of Research: Methods and Applications]

I have used economic geography and industrial organization economics every day — the cognitive skills provided by geography as a discipline have served as the best preparation for applied research in diverse institutions. These employers needed people to be able to think out of the box. I had to devise solutions and present them to management. 

I was reliving Allan Pred’s unique approaches to research and the broad spectrum of topics he has written about, so creatively.

“Data Modeling” is my middle name. I was a geographer, an economist/econometrician, a statistician/research designer. An urban planner/transportation analyst, an organization theorist, a social scientist — a “variant” of Prof. Allan Pred not in academia, but in multiple sectors of the American economy that needed people who used critical thinking processes and methods in formulating original actionable solutions.

It was the confluence of existential forces that assisted my survival while thriving in the non-academic world, where the rules of behavior are less crisp than the determinants for the “pathway to academic tenure.”

 

  • The Mentor

Often musing on Allan Pred’s creativity and confidence, I saw a very slender blue-eyed lion, the king of all mammals, walking in full command of the Berkeley hills or bicycling uphill. Never rushing, running or escaping, it was always full sun, no shadows in sight, the dominion king arrived, The Chairman.

Other Mentors

The three signatures on my doctoral dissertation, are:

 

  • The Institution

The aura of Berkeley as an institution of excellence has been pervasive. No one could pronounce my name. (No hiring manager could go wrong, all reported with assertiveness, “We have hired a Berkeley PhD and an ex-director from SRI”.)

 

  • The Candidate

The unique “born with” a “primordial” endowment that Aviva had demonstrated since the 6th grade in Israel – an ability to produce original syntheses from very complex multi-factor interactions.

For 25 years a quantitative economic geographer in the non-academic world – a top designer of algorithm-based decision support systems (DSS) for operations management problems [N=26 modeling solutions completed by 2004].

I have addressed:

  • a most diverse range of business and organizational problems involving decision-making under uncertainty with complex constraints;
  • in multiple industries: automotive, chemical, advanced materials, paper & allied products, computer hardware, computer software, B-to-B electronic commerce, financial sector, adaptive educational testing, and education publishing;
  • for several functional domains: product planning, marketing and market research, finance, geographic plant and HQs location decisions, and resource allocation for R&D initiatives;
  • in half a dozen theoretical & applied disciplines: operations research, behavioral economics, multivariate non-linear statistics, econometrics, urban geography, and city transportation planning;
  • Listed here is a sample of problems that I solved and/or designed the modeling for, including, technology assessment models, modeling competitiveness, software and intellectual property (IP) pricing models, real-time supply chain planning, new product demand rorecasting, and modeling computer hardware obsolescence.

Enjoyed every moment of it and was/am so very proud to have been through the trajectory from University of California, BERKELEY to the non-academic world, for which Berkeley prepared me so well.

 

Advertisements

Edward Abrahams, President, Personalized Medicine Coalition: “A Focus on Cost Instead of Value Threatens the Future of Personalized Medicine”

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

 

“A Focus on Cost Instead of Value Threatens the Future of Personalized Medicine”

by Edward Abrahams, President, Personalized Medicine Coalition

May 23, 2018

One size fits all never worked as a strategy for the fashion industry. Or the auto, furniture, and most other industries. It shouldn’t be the strategy for medicine either, but unfortunately more often than not it is. And it may stay that way if the focus on cost rather than value precludes the improved health care strategies made possible by personalized medicine.

According to the World Health Organization, an effective health system requires “reliable information on which to base decisions and policies.” The evolving field of personalized medicine delivers just that kind of information in the form of data about the unique biological characteristics of each patient. Doctors can often use that information to make medical decisions based on an understanding of how a patient will respond at a molecular level to a specific therapy. This helps ensure that therapies are prescribed only to those who will benefit from them, sparing side effects and expenses to those who will not.

Although the majority of patients say they aren’t yet aware of personalized medicine, they also say they don’t want to miss out on this opportunity.

Survey results released Wednesday by the Personalized Medicine Coalition, a nonprofit education and advocacy organization, and GenomeWeb, an online news service, show that although two-thirds of Americans have never heard of personalized medicine, two-thirds of them also react positively to a description of the approach and only 1 percent react negatively to it. The overwhelming majority agree that replacing one-size-fits-all, trial-and-error medicine with an approach that proactively identifies the right treatment for the right patient is worth pursuing and paying for.

One of every four new drugs approved by the Food and Drug Administration over the last four years was designed to become a personalized (or “targeted”) therapy that zeros in on the subset of patients likely to respond positively to it. That’s a sea change from the way drugs were developed and marketed 10 years ago.

Some of these new treatments have extraordinarily high list prices. But focusing solely on the cost of these therapies rather than on the value they provide threatens the future of personalized medicine.

Most Americans are unfamiliar with the principles and benefits of personalized medicine, with only 13 percent of survey respondents indicating that they feel “very informed” about the field. So they are not yet asking policymakers to make the changes that would ensure continued investment in and adoption of personalized medicine. Patients, like health systems, are still locked into a one-treatment-fits-all world.

At the same time, most policymakers are not asking the right questions about the benefits of these treatments for patients and society. Influenced by cost concerns, they assume that prices for personalized tests and treatments cannot be justified even if they make the health system more efficient and effective by delivering superior, longer-lasting clinical outcomes and increasing the percentage of patients who benefit from prescribed treatments.

Goldman Sachs, for example, issued a report titled The Genome Revolution. It argues that while “genome medicine” offers “tremendous value for patients and society,” curing patients may not be “a sustainable business model.” The analysis underlines that the health system is not set up to reap the benefits of new scientific discoveries and technologies. Just as we are on the precipice of an era in which gene therapies, gene-editing, and immunotherapies promise to address the root causes of disease, Goldman Sachs says that these therapies have a “very different outlook with regard to recurring revenue versus chronic therapies.”

In other words, Goldman Sachs suggests that if the pharmaceutical industry wants to make money, it should be cautious about developing one-shot therapies that cure patients and lower costs over time, because decision-makers are more focused on the price of a product than its value to a particular patient or to the health system itself.

If ongoing concerns among policymakers and the public add to the validity of this logic by discouraging payers from covering personalized “cures,” Goldman Sachs and others could choose not to make investments in innovative medicines that patients clearly want and need.

It falls on Congress, the FDA, and the Centers for Medicare and Medicaid Services to put in place an infrastructure that supports personalized medicine by:

  • Spearheading the efficient approval of personalized tests and treatments
  • Developing innovative reimbursement models that provide incentives for targeting treatment to only those patients who will benefit
  • Implementing programs that encourage the clinical adoption of personalized medicine by health systems around the country

With such efforts, policymakers can accelerate the pace of medical progress upon which patients and the health system depend.

As Tango Therapeutics President and CEO Dr. Barbara Weber summarized at the 12th Annual Personalized Medicine Conference at Harvard Medical School in 2016, “It’s not really ‘should we do this.’ We have to do this. We don’t get to decide what the biology of these diseases are, we just have to work with it.”

SOURCE

From: “Christopher Wells (PMC)” <cwells@personalizedmedicinecoalition.org>

Date: Thursday, May 24, 2018 at 11:18 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: PMC in STAT News: “A Focus on Cost Instead of Value Threatens the Future of Personalized Medicine”

Aviva:

We would be honored if you highlighted the piece on your channels. I know you have a broad reach.

 Thank you so much.

 Best,

 Chris

Christopher J. Wells, M.P.A.

Vice President, Public Affairs

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

 

Personalized Medicine Coalition

Blog:Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org  

 

 


Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy

Curator: Aviva Lev-Ari, PhD, RN

 

The article below identifies the following four Alternative Careers for PhDs in the Non-Academic World:

  • Science Writer/Journalist/Communicator
  • Science Management
  • Science Administration
  • Science Entrepreneurship

CASE STUDY on Pursuit of Science Careers in Business After a PhD

The Voice of Aviva Lev-Ari, PhD, RN on Professional Self Re-Invention: From Academia to Industry

Great advice is offered in the article by Ankita Gurao in bitesizebio.com, below

My advice is as follows:

  • Every motivated student should pursue the highest degree they are able and willing to.
  • The structural changes in the economy are driven by a record pace of technological innovations in the DIGITAL economy.
  • ONLY IF YOU ARE OVER QUALIFIED you are in fact prepared for the number of CAREERS you will need to pursue in one’s life time. Therefore earning a PhD is a MUST.
  • The Demand for PhD in the Marketplace should not be the determinant for pursuing an advanced degree.

I am presenting here a PROFILE of a Berkeley PhD’83 that had pursued a Career in the Business Sector of the Economy

Professional Career post UC, Berkeley:

  • SRI, Int’l, 1985-1988,
  • AMDAHL Corporation, 1988-1989
  • MDSS, 1991-1994
  • MITRE Corporation, Bedford, MA, 1995-1997,
  • PSC, 1997-2001,
  • McGraw-Hill, 2002-2003,
  • LPBI Group – 2012 – Present

See,

 

Original article

Ways to Pursue Science Careers in Business After a PhD

5/22/2018

Science Writer/Journalist/Communicator

I am sure that you’re familiar with the large amount of jargon in the scientific literature. As a science writer or communicator, your job is to “translate” this jargon into layman terms. Imagine if you were asked to discuss the same content with your bestie over a steaming cup of coffee. Obviously, that would be an easy and enjoyable task. And this could be your career! All you need is a little training.

To get that training, you can find available fellowships for learning different communication methods. Also, there are online science communication courses. Here are a few to help you with your journey:

Science Management

Aside from doing the experimental work of science, you also have to consider the managerial aspects. You have to consider where you should submit your paper (and your back up plan if that journal rejects your paper), plan for your upcoming PI meeting, and order that crucial reagent for the experiment you will conduct next month. And many, many more things!

Science management focuses on solving these problems. It uses some skills that you likely already have in your toolbox—like managing people, resources, and so on.  After completing your PhD, you can get formal management training that would allow you to enter a variety of fields. For example, you could become a:

    • project manager
    • science director
    • scientific program manager
    • industry R&D manager
    • curator
    • analyst
    • consultant

Science Administration

This career focuses more on making policy than management. These careers tend to look at the impact that science makes on society or how science (in general) should be conducted. Examples of such careers include:

  • regulatory affairs executive
  • patent attorney
  • scientific conference organizer
  • medical information executive
  • university school liaison adviser
  • forensic science administrator

Science Entrepreneurship

Ideally, our research should better society. As a graduate student, we are provided with a nourishing environment for intellectual pursuits. On the other hand, industry converts these ideas into a business affair that can generate money. You can combine these two ideals in science entrepreneurship.

If you have a great scientific mind and a zeal to bring your ideas into the ‘real world’ by taking calculated risks, then the entrepreneurship is something you should consider. Your college or university likely has a technology transfer office or an entrepreneurship center that can help you get started. Many of these centers include basic instruction on funding, researching competitors, market research, intellectual property issues, and many more topics. Those basics include networking, researching the market, knowing the preexisting competitors, financial security, intellectual property aspects, and much more.

Hopefully, this article gave you insight into the many opportunities available for you outside of academia!

References

  1. Weissmann, Jordan. (July) The Stagnating Job Market for Young Scientists. Slate.
  2. McDowell G. (2016). The Fool’s Gold of Ph.D. Employment Data. Science.
  3. Science Council (2018). 10 types of scientist.

SOURCE

https://bitesizebio.com/38498/ways-to-pursue-the-business-of-science-after-a-ph-d/?utm_source=facebook&utm_medium=social&utm_campaign=SocialWarfare

Other related articles published in this Open Access Online Scientific Journal include the following:

170 articles on Scientist Career Considerations

https://pharmaceuticalintelligence.com/?s=Scientist+Career+Consideration


Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

Curator Aviva Lev-Ari, PhD, RN

 

This curation has four parts:

 

Part 1: Re-Tweets by @AVIVA1950 

Part 2: Tweets earned impressions over 5/15 – 5/17/2018 Period – 2018 BioIT, Boston

Part 3: Re-Tweets by @pharma_BI – see complete list on @pharma_BI Twitter.com page

Part 4: Original Tweets by @AVIVA1950 – Real Time Coverage of 2018 BioIT, Boston

 

 

Part 1: Re-Tweets by @AVIVA1950

  1.   Retweeted

    Aviva Lev-Ari Retweeted Stinus Lindgreen

    Aviva Lev-Ari added,

    2.  Retweeted

    Discussing how to build a data science team: Many different skill sets needed. While IT support is required, the data science team is really all about the data

  2.   Retweeted

    Des Higgins: code ClustalW frozen for more than 10 years, but still used… quality

  3.   Retweeted

    Audience Q: When do you think the machines will be routinely making the DX? Boguski: Sooner than you think.

  4.   Retweeted

    Towards Tailor-Made Drugs with AI-Driven Drug Design – Dr. van Daelen of is speaking at now in the amphitheater.

  5.   Retweeted

    BridgeDb poster up at , no 30

  6.   Retweeted

    RT finchtalk: keynote by carlzimmer on genes and heredity. Discusses subtle effects of HGMA2 – sadly no structure yet – on heigh…

  7.   Retweeted

    waiting for you at ! come over to booth 646 to find out why has been nominated !

  8.   Retweeted

    panel describing importance of , not just big data, whole work flow from data creation to insights & decisions

  9.   Retweeted

    Job Board!!! Great new addition

  10.   Retweeted

    we need tech for proteomics that is as good as the tech is for genomics — Lihua Yu

  11.   Retweeted

    carlzimmer is concerned that as we have more access to our genes, we will fall back on old ideas of heredity to understand

  12.   Retweeted

    Diagnostic testing is a key factor for modern-day advanced healthcare. The wall between diagnostic physicians and treating physicians is still a challenge. Dr. Boguski’s keynote

  13.   Retweeted

    Tom Plasterer : offers a nice way to close the RDF open world assumption, which helps to identify if a dataset has achieved full discoverability by hitting a set of given metadata requirements

  14.   Retweeted

    Live from Bio-IT World booth #227: we’re excited to announce that our featured partner this year is . Come chat with us about Vertically Integrated Precision Medicine!

  15.   Retweeted

    L.Omberg of helps us understand how to develop digital biomarkers through crowd sourcing at

  16.   Retweeted

    Great closing session led by our friends and a great panel that agreed that HI will save us all and is the clown car of our industry…

  17.   Retweeted

    Heard at from : is “the clown car of our world these days. … It’s being driven by a bunch of grifters who want to profit off of their magical math tokens.”

  18.   Retweeted

    Boguski: Gathering data frm 350K Thai employees+dependents (genome+microbiome), family & Med history; wearable health monitoring.

  19.   Retweeted

    The Town Hall is coming up later today at . We had some great questions last year – here’s discussing how Scientists and IT both have a responsibility for cloud infrastructure.

  20.   Retweeted

    Data is like art, if you don’t know the provenance the value significantly decreases

  21.   Retweeted

    Screen data from different assay types for more accurate results. at Booth 340

  22.   Retweeted

    Des Higgins , Benjamin Franklin winner celebrates . Integrating data remains our challenge

  23. Aviva Lev-Ari Retweeted Stinus Lindgreen

    Aviva Lev-Ari added,

  24.   Retweeted

    Sitting in one of the last sessions at listening to a talk on RNA. I am being told that mRNAs do no just encode proteins – they form secondary structures. I am shocked. Shocked! Did you know this, ?

  25.   Retweeted

    And that’s a wrap! Thank you for a great conference

  26.   Retweeted

    Andras Volford, is speaking about Project Haystack: universal access to corporate research history

  27.   Retweeted

    . poster up at , no 28

  28.   Retweeted

    Higgins driving home the point that number of citations does not equate to importance. Sometimes inverse!

  29.   Retweeted

    foster an innovative culture — Tanya Cashorali builds a sandbox and encourages data scientist to play

  30.   Retweeted

    Grab your spot! Our last Spotlight presentation of the day will start in less than an hour: A Freeing Approach to Search and Analytics Leads to Faster Drug Discovery

  31.   Retweeted

    Celebration at the booth for Best of Show Judges Award!

  32.   Retweeted

    Getting sequences in 1984: write a letter to GenBank or EMBL and they’d mail you a book! HigginsDes

  33.   Retweeted

    Wonderful historical perspective on open access and data sharing from the legendary Des Higgins, this year’s recipient of the Benjamin Franklin Award.

  34.   Retweeted

    if we’re sharing data, we need to be responsible with how we use it — Jerald Schindler

  35.   Retweeted

    Have I not been paying attention in past years, or is “data hub” a new buzzword at ? Are there others?

  36.   Retweeted

    Next panel question – scientists often “protective” of their data. How to break data silos and encourage a data sharing culture?

  37.   Retweeted

    Roman Affentranger defines “advanced analytics” as “anything goes … so long as it is more than traditional business intelligence”

  38.   Retweeted

    An unwieldy system, and it wasn’t open access. In 1989 Patricia Kahn asked that journals require sequences to be shared pre-pub.

  39. Aviva Lev-Ari Retweeted Cambridge Innovation

    Very important to remind initial step in democratization of Data and milestone . See Open Access online Scientific Journal +5,300 scientific articles in BioMed, 16-Volume BioMed e-Series on Amazon.con

    Aviva Lev-Ari added,

  40.   Retweeted

    Important point being raised by at : We have many patients who willingly and with consent provide us with valuable samples. They expect us to do something with them. We are ethically obliged to use them, not just store and destroy them after X years. Stop waste.

  41.   Retweeted

    Jabe Wilson talks about work by on finding experimental mice housing conditions in the literature

  42.   Retweeted

    I’m pretty sure that was the official name of this award, right ? !

  43.   Retweeted

    it’s not the formula you use, but WHY you used it – Jerald Schindler

  44.   Retweeted

    is concerned that as we have more access to our genes, we will fall back on old ideas of heredity to understand

  45.   Retweeted

    Last keynote by at Fascinating walk through the infancy of genetics.

  46.   Retweeted

    , – The purpose of visualization is insight not pictures.

  47.   Retweeted

    Bryan Takasaki is up next discussing AstraZeneca’s R&D Data Hub — connecting data from multiple silos to enable analytics

  48.   Retweeted

    Excited to announce that the winner of our complimentary whiteboard consulting engagement is Optum Genomics! Congratulations and we’ll be in touch with more information.

  49.   Retweeted

    is coming to an end. The last speaker showed a great quote from |s Baldoni about the need for all of us to share data: There is so much data out there on failed experiments, on molecules, that we are obliged to share – avoid unnecessary trials and tests on patients.

  50.   Retweeted

    Ending the day with a co-presentation by Krista McKee, and Raveen Sharma, on leveraging an R&D data hub platform for next generation of clinical data review

  51.   Retweeted

    Attending ? Don’t miss the Plenary Panel on Wednesday 5/16. Alongside a great team of speakers, TCB’s will cover applications of data science, implementation best practices, and industry predictions.

  52. Aviva Lev-Ari Retweeted TCB Analytics

    Amazing event by was amazing two, 16 tracks, great talks, community

    Aviva Lev-Ari added,

  53.   Retweeted

    Best of show at ? member ! Congratulations!!

  54.   Retweeted

    Well deserved! Desmond Higgins, father of CLUSTAL and T-COFFEE, receives the Benjamin Franklin Award at

  55.   Retweeted

    Our Microglia and Neuron describing how to manage our lifestyle on molecular basis have just won the CHI Poster Competition at ! Thanks to all who voted! , your art is excellent.

  56. Aviva Lev-Ari Retweeted sci.AI

    Aviva Lev-Ari added,

  57.   Retweeted

    Congrats to Desmond Higgins for 2018 Franklin Award . Great talk on progress in

  58. Aviva Lev-Ari Retweeted Jane Reed

    The historical perspective provided most valuable for understanding in

    Aviva Lev-Ari added,

  59.   Retweeted

    Among Galton’s groundbreaking ideas: twin studies.

  60.   Retweeted
  61.   Retweeted

    It appears this year’s buzz word Data Science has replaced Bioinformatics ….

  62.   Retweeted

    Many Congratulations to the winner of Best of Show at from MediSapiens member !

  63.   Retweeted

    Everybody should become a Data Scientist instead of being a friend of a Data Scientist

  64.   Retweeted

    Dr. Stephen Kingsmore, CEO of , reacts to yesterday’s news about Edico Genome and shares his vision of rapid, scalable sequencing. For more information, please visit

  65.   Retweeted

    Thanks for a grand time. I feel drained but so FAIR. Also found out I suck at both ping pong and cornhole so I acquired a higher level of self-knowledge.

  66.   Retweeted

    Intel uses convents to accelerate copy number detection in GATK

  67.   Retweeted

    Congratulations to & for winning a Best Practices award for a Patient-Centric Platform for Clinical Research:

  68.   Retweeted

    . Height is a great example of how hard it is to get from knowing something is heritable to understanding how

  69.   Retweeted

    Getting sequences in 1984: write a letter to GenBank or EMBL and they’d mail you a book!

  70.   Retweeted

    Congratulations to & for taking home a Best Practices award for Project Platypus (details: )

  71.   Retweeted

    Enoch Huang , Pfizer is sharing the things he didn’t know he needed to know before attempting to implement a cloud-based genomics data environment

  72.   Retweeted

    . gives his first official lecture to promote his fabulous new book “She Has Her Mother’s Laugh” — great “get” by Expo!

  73.   Retweeted

    What changed to make data science so core? Lihua Yu notes we now can create large high quality data sets and the needed infrastructure. She also noted will/should democratize data.

  74. Aviva Lev-Ari Retweeted Carmen Nitsche

    Aviva Lev-Ari added,

  75.   Retweeted

    Boguski: “Precision medicine starts with precision diagnostics.” Good point!

  76.   Retweeted

    Data should be Persionalized Actionable Collaborative and Explainable (PACE) –

  77.   Retweeted

    create environments that motivate the team so that they do share data – John Reynders

  78.   Retweeted

    At asks the question “how much data is there on something we haven’t tried yet?” talking about the combinatorics challenges of cancer treatment (track 16)

  79. Aviva Lev-Ari Retweeted jahendler

    This is an area that will make the biggest contributions to serving

    Aviva Lev-Ari added,

  80.   Retweeted

    : Everyone, either now or very soon in the future, is going to need to be hands on with their data.

  81.   Retweeted

    We are still using the same tools/dyes we’ve been using to diagnose cancer since 19th century. It’s not even FDA-approved

  82.   Retweeted

    : Data science can include data wrangling, summarization, exploration and visualization. Ultimately, you’re optimizing the decision-making process. How you go from data to insight is less important than the quality of the results.

  83.   Retweeted

    Great point from John Reynders in the panel at – data science should help us decide the next relevant question to ask. True.

  84.   Retweeted

    We’re sharing ’s tweets today for . Learn about his work applying computer science to problems in in this profile:

  85.   Retweeted

    Yu: We have a big responsibility to democratize data

  86.   Retweeted

    Touching down at the Seaport with for ! Come say hi!

  87.   Retweeted

    “If you want to know if our drug is truly effective the best place to do it is not the clinic. We need to do it in the wild” – Digital Biomarkers in Pharma R&D.

  88.   Retweeted

    Don’t miss Kurt Kuckein Architecting for Success with Machine Learning Data Platforms at 5:15PM in the Amphitheater

  89.   Retweeted

    Damn. BioTeam is all over today. Good chance to see some of our folk who don’t normally do a lot of public talks in action. Plan your schedule accordingly and then come visit us in booth #441.

  90. Aviva Lev-Ari Retweeted Chris Dagdigian

    Bravo was impressed with attends since 2002

    Aviva Lev-Ari added,

  91.   Retweeted

    Check out my poster at to learn how is enabling in creating a digital Noah’s Ark

  92. Aviva Lev-Ari Retweeted Maria Simbirsky

    BRAVO TO@dnanexus

    Aviva Lev-Ari added,

    Translate Tweet

  93.   Retweeted

    And here they are… the results of a 25 hour time window of hacking at the hackathon! Some through better understanding of the metrics but a lot also by adding documentation, code and references to existing data sources.

  94.   Retweeted

    Registration for the 2018 Bio-IT World Conference & Expo is now OPEN. Ask about our 1 on 1 Networking Meetings.

  95.   Retweeted

    Spotted the Starfish at

  96. Aviva Lev-Ari Retweeted Kees van Bochove

    Bravo for these four steps of in

    Aviva Lev-Ari added,

  97.   Retweeted

    Reynders: is a person asking a question and human insight pushing an answer forward.

  98.   Retweeted

    starts today! Looking forward to three days of collaboration and celebration with the Bio-IT Community!

  99.   Retweeted

    RT stinuslindgreen: Last keynote by carlzimmer at Fascinating walk through the infancy of genetics.

  100. Aviva Lev-Ari Retweeted Cambridge Innovation

    History of as foundation for discussing and as evolving since mid 19th Century

    Aviva Lev-Ari added,

  101.   Retweeted

    Bio-IT World Editor Allison Proffitt welcomes a panel at . Tanya Cashorali () of TCB Analytics, Jerald Schindler of , John Reynders of & Lihua Yu of

  102. Aviva Lev-Ari Retweeted Stinus Lindgreen

    The challenge is on the Genomic crowd to accomplish that challenge, will welcome reinvention if brought to them

    Aviva Lev-Ari added,

  103.   Retweeted

    Learning about at

  104.   Retweeted

    We are getting ready for the last day at – yesterday I won a car. How to top that today?

  105.   Retweeted

    April Bingham Retweeted Helena Deus

    From my math about 18-20% female participants! Good to see diversity was top of mind for organisers as well.

    April Bingham added,

  106.   Retweeted

    The Town Hall is just about to start, here’s one last clip of from 2017 discussing MPI and HPC schedulers and if reports of their death are greatly exaggerated

  107.   Retweeted

    Bio-IT world expo: Well done with a gender balanced data science panel!!

  108.   Retweeted

    “The truly happy and successful Enterprise IT folks are generalist’s.” Organisations need to invest money and time in re-training, cross-training and investing in their current staff to bring new technologies to the table. @ the expert panel.

  109.   Retweeted

    discussing heredity and genes during his keynote presentation at

  110.   Retweeted

    We’re absolutely thrilled to announce our breakthrough scientific search engine iScite by won the Best Of Show Award 2018!!

  111.   Retweeted

    We are very excited to be part of ! Together with Illumina’s sequencing portfolio, the DRAGEN Bio-IT Platform enables customers to benefit from reduced investment in compute infrastructure, and accelerated result times.

  112.   Retweeted
  113.   Retweeted

    John Veystman assures us that won’t take over our jobs — AI is a partner to our human intelligence

  114.   Retweeted

    Our poster “Efficient curation and real-time querying of clinical and genomic data for 500.000 samples” was chosen as the poster competition winner at ! Come and check the winner at poster board 31

  115. Aviva Lev-Ari Retweeted MediSapiens

    BRAVO FOR POSTER COMPETION WINNER

    Aviva Lev-Ari added,

  116.   Retweeted

    What is the latest tech that impressed you? : I’m excited by everything that comes out of

  117. Aviva Lev-Ari Retweeted Mary-Ann Moore

    Very proud of for powerful technology

    Aviva Lev-Ari added,

  118.   Retweeted

    We’ve launched PetaSuite Cloud Edition at Bio-IT World 2018 and we’re proud to announce that we’ve won Best of Show. Congratulations to the whole team!

  119.   Retweeted

    : 70-80% of the hospital EHR is laboratory data. And this is about to get a lot more with digital pathology. In fact if all cancer pathology in U.S. would go digital it would produce almost a exabyte of data per year.

  120.   Retweeted

    Make your data more . Here are some tips on how to do this: Come to our booth 418 to discuss data FAIRification.

  121.   Retweeted

    I’ve intentionally stepped away from public speaking at partially as a way to force awesome Bioteam coworkers to replace me at the podium. Psyched to see John getting ready for a tech talk about IRODS for life sci data management — Peggy is pretty awesome as well 🙂

  122.   Retweeted

    “This company has been pushing the boundaries for the past 10 years in life sciences. With their new product they have brought natural language to the masses.” – judges. Congratulations team judges lifetime award!

  123.   Retweeted

    The Data hackathon teams: – datahub with PDX models – building on BioAssay protocols Impressive lineup, these are major biomedical data resources!

  124.   Retweeted

    We are very excited to welcome Edico Genome! Together with Illumina’s sequencing portfolio, the DRAGEN Bio-IT Platform enables customers to benefit from reduced investment in compute infrastructure, and accelerated result times.

  125.   Retweeted

    Yes! The -BASE platform for clinical studies with wearable sensors has won the award in data integration & management!

  126.   Retweeted

    No Man-nels at – Kudos to the organizers for ensuring gender balanced panels!

  127. Part 2: Tweets earned impressions over5/15 – 5/17/201

    •   Retweeted

      Thank you Bio-IT community for making a truly memorable event! See you next year in Boston: April 16-18, 2019

      Part 2: Tweets earned impressions over 5/15 – 5/17/2018 Period – 2018 BioIT, Boston

    Aviva Lev-Ari @AVIVA1950  52mThank you twitter.com/stephsteeves7/…

    12

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18Amazing insight by @stinuslindgreen #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/stinuslindgree…

    32

    1

    3.1%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18Very important to remind initial step in democratization of Data and milestone #OpenAccess. See Open Access online Scientific Journal pharmaceuticalintelligence.com +5,300 scientific articles in BioMed, 16-Volume BioMed e-Series on Amazon.con #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/ciinstitute/st…

    44

    2

    4.5%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18#BioIT18 Amazing event by @CHI #Expo was amazing two, 16 tracks, great talks, #datascience community @AVIVA1950 @Pharma_BI twitter.com/tcbanalytics/s…

    41

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18BRAVO for #PosterAward #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/sci_ai/status/…

    33

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18The historical perspective provided @DesmondHiggins most valuable for understanding #openaccess #Genomics in @Europe #BioIT18 #FranklinAward @AVIVA1950 @Pharma_BI twitter.com/jz_reed/status…

    41

    1

    2.4%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18Many strides made already in #datascience #computation #infrastructure #democratization #data large #datasets #data #quality #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/cnitsche/statu…

    75

    1

    1.3%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18This is an area that #AI will make the biggest contributions to #Genomic serving #Medicine #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/jahendler/stat…

    100

    4

    4.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18#DataScience #numerical #technology to advance #science and #theoretical #hypotheses #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/stinuslindgree…

    181

    6

    3.3%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18Bravo @BioTeam was impressed with #VariantQueryTool #BioIT18 @AVIVA1950 @Pharma_BI attends @BioITWorld since 2002 twitter.com/chris_dag/stat…

    38

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18BRAVO TO@dnanexus #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/msimbirs/statu…

    46

    2

    4.3%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18Bravo for these four steps of #workflow in #Bioinformatics #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/keesvanbochove…

    36

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18History of #Genetics as foundation for #Genomics discussing #heredity and #environment #epigenetics as evolving since mid 19th Century @England #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/ciinstitute/st…

    44

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18The challenge is on the Genomic crowd to accomplish that challenge, #radiotherapy will welcome reinvention if brought to them #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/stinuslindgree…

    38

    2

    5.3%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18BRAVO FOR POSTER COMPETION WINNER #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/medisapiens/st…

    34

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 18 Very proud of @Linguamatics for #textmining powerful technology #BioIT18 @AVIVA1950 @Pharma_BI twitter.com/usmaryann/stat…

    284

    9

    3.2%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17Bio-IT World Announces 2018 #AwardWinners – May 17, 2018 pharmaceuticalintelligence.com/2018/05/17/bio… via @Pharma_BI #BioIt18 @AVIVA1950

    96

    1

    1.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17#BioITWorld Announces 2018 #BestOfShow #Award Winners – May 17, 2018 pharmaceuticalintelligence.com/2018/05/17/bio… via @Pharma_BI

    55

    4

    7.3%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17@YueWebster @Lilly TXG – MAP to compare Treatments: Apoptosis post treatment with Tunicamycin Red Induced expression Green supressed expression Hypetrophy caused by antibiotic Tunicamycin #BioIT18 @pharma_BI @AVIVA1950

    126

    4

    3.2%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17Bravo @Linguamatics #BioIT18 @Pharma_BI @AVIVA1950 twitter.com/USMaryAnn/stat…

    196

    6

    3.1%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17@YueWebster, Informatics Capabilities, Research IT, @EliLilly How to build TXG – MAP #DataInput #Trainingset#DrugMatrix #Algorithms – 415 co-expression module #Interpretation #Geneontology #BioIT18 @pharma_BI @AVIVA1950

    151

    6

    4.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 172018 CHI’s BioIT World conference THURSDAY, MAY 17 | 8:00 – 9:45 AM – #Awards and #Keynote pharmaceuticalintelligence.com/2018/05/17/201… via @Pharma_BI

    73

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17 2018 BioIT AWARDS Judges’ Prize WINNER Alexion Pharmaceuticala nominated by EPAM Systems – SmartPanel: Rare DIsease Diagnostics – Algorithm Competition – automate from MDs Notes #BioIT18 @pharma_BI @AVIVA1950

    282

    4

    1.4%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17Bio-IT World Personalized & Translational Medicine WINNER @MGH NeuroBank Patient-Centric Platform Clinical Research #BioIT18 @pharma_BI @AVIVA1950

    190

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17Bio-IT World IT Infrastructure- WINNER Celgene #BioIT18 @pharma_BI @AVIVA1950

    201

    2

    1.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17 Bio-IT World Clinical & Health IT – WINNER TakedaPharmaceutical Nominated by Deloitte #BioIT18 @pharma_BI @AVIVA1950

    174

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17Bio-IT World Best Practices Awards – WINNER AstraZeneca, Nominated by Genedata IMED BioTech Unit #BioIT18 @pharma_BI @AVIVA1950

    186

    1

    0.5%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17Franklin Award @bioitworld goes to Desmond G. Higgins, PhD, Professor, Biochemistry, University College Dublin Conway Institute of Biomolecular & Biomedical Research #BioIT18 @pharma_BI @AVIVA1950

    146

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 17@BenjaminFranklin #Awards and #LaureatePresentation @JWBizzaro, Managing Director, @Bioinformatics.org Presented Award to @DesmondGHiggins @DublinCollege #OpenAccess #Clustal #BioIT18 @pharma_BI @AVIVA1950

    175

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 16Synopsis Day 1 Track 7 – #NGSInformatics 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center pharmaceuticalintelligence.com/2018/04/05/201… via @Pharma_BI

    135

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 16#LIMS or #ELN @KevinCramer #CEO @SapioSciences 2015 #Exemplar support #adHocExperimentation clean sheet design create RQS for Samples Assign processes Track progres register Samples Register plates Aliquoting Storage Graphical register consumables #BioIT18 @pharma_BI @AVIVA1950

    308

    1

    0.3%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 16@ChavaKimchiSarfaty @FDA @CBER @OTAT #InSilico #translationkinetics based solely on calculated #codonusage #frequency #Ribosomalprofiling data do not correlate with #codonOptimization #Genetically engineered therapeutics – benefit from Codon Opt #BioIT18 @pharma_BI @AVIVA1950

    258

    6

    2.3%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 16 @JackDiGiovanna @SevenBridges #MicrosatelliteInstability short tanden repeats of 1 to 6 base-pairs: #Detections #MSImutations in #somatic #variants #ProfilingHeterogeneity vs #TumorPurity #Clinical #MSIdata #BioIT18 @pharma_BI @AVIVA1950

    160

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 16@LeonardLipovich #Human #BreastCancer #LongNonCoding #RNA #Mechanism: #MisTranslation #GeneTranslationInfidelity: why are only UAG and UGA, never UAA, #referencegenome #stopcodons are affected #BioIT18 @pharma_BI @AVIVA1950

    162

    0

    0.0%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 15#DigitalPathology #ML #scanners #IntegratedPrecisionDiagnostics #Genomics #Radiology #Pathology @CPMedicalCenter #BioIT18 @pharma_BI @AVIVA1950

    182

    1

    0.5%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 15#BioIT18 @pharma_BI @AVIVA1950 #DiagnosticsTesting drive #medicaldecisions @MGH Dx invented #laboratory mgm systems #Radiology #Pathology #AI #ML brings solutions

    283

    2

    0.7%

    View Tweet activity

    Aviva Lev-Ari @AVIVA1950  May 15 #BioIT18 #pharma_BI #AVIVA1950 deeper #workflow by #AI #ML @DDN #highperformance #storage

    203

    0

    0.0%

     

    Part 3:  @pharma_BI Re-Tweets

    [@pharma_BI Retweeted]
    @pharma_BI
    @pharma_BI
    ·
    May 17
    2018 CHI’s BioIT World conference THURSDAY, MAY 17 | 8:00 – 9:45 AM – Awards and Keynote
    pharmaceuticalintelligence.com
    @pharma_BI
    @pharma_BI
    @Pharma_BI
    ·
    May 17
    Embedded
    @pharma_BI
    @pharma_BI
    @Pharma_BI
    ·
    May 16
    2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center
    pharmaceuticalintelligence.com
    @pharma_BI
    @pharma_BI
    @Pharma_BI
    ·
    May 16
    2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center
    pharmaceuticalintelligence.com
    Cambridge Innovation
    Cambridge Innovation
    @CIInstitute
    ·
    May 17
    RT stinuslindgreen: Last keynote by carlzimmer at #BioIT18 Fascinating walk through the infancy of genetics.
    Embedded
    2
    5
    @pharma_BI Retweeted
    The Jackson Laboratory
    The Jackson Laboratory
    @jacksonlab
    ·
    May 17
    7
    14

    @pharma_BI
    @pharma_BI
    @Pharma_BI
    ·
    May 17
    2018 CHI’s BioIT World conference THURSDAY, MAY 17 | 8:00 – 9:45 AM – Awards and Keynote
    pharmaceuticalintelligence.com
    @pharma_BI
    @pharma_BI
    @Pharma_BI
    ·
    May 17
    Embedded
    @pharma_BI
    @pharma_BI
    @Pharma_BI
    ·
    May 16
    2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center
    pharmaceuticalintelligence.com
    @pharma_BI
    @pharma_BI
    @Pharma_BI
    ·
    May 16
    2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center
    pharmaceuticalintelligence.com

    Part 4: Original Tweets by @AVIVA1950

    1. Updated Synopsis Track 7: in 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center via

    2. Synopsis Track 7: in 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center via

    3. , MD @MGH and misalignment of data owners SW for MDs @ReginaBarzilay effective for expertise while data is locked in national tasks

    4. , MD, @MGH @HMSTargeted in more than another diseases matching to system does not exist yet in large scale @ReginaBarzilay Probabilistic methods instead of population studies

    5. , PhD, Research Professional, Booth School of Business, Institute for & , @UniversityofChicago Highest for , , , , , Results: 84 new estimates

    6. , Dir Bioinformatics, Cloud SW development Partner DNAnexus @MicrosoftASURE in 2017, St.Jude Cloud 3000 pediatric cancer survivors – Optimize therapy to improve quality of life Gene fusions – 42 days – Leukemia RNA Seq workflow

    7. @YueWebster TXG – MAP to compare Treatments: Apoptosis post treatment with Tunicamycin Red Induced expression Green supressed expression Hypetrophy caused by antibiotic Tunicamycin

    8. Aviva Lev-Ari Retweeted Mary-Ann Moore

      Aviva Lev-Ari added,

    9. @YueWebster, Informatics Capabilities, Research IT, How to build TXG – MAP – 415 co-expression module

    10. , Scientist, Research Informatics, @RochePharmaceuticals SOLUTION – 150 hours = is the most time consuming Ensebl REST API Endpoints

    11. Award-winning Science Writer; Columnist, New York Times; Author of She Has Her Mother’s Laugh, 2018) Up to 30 top contributed the largest to

    12. Plenary Keynote Presentation: Height and Intelligence: Exploring the Complexity and Controversy of Heredity

    13. 2018 BioIT AWARDS Judges’ Prize WINNER Alexion Pharmaceuticala nominated by EPAM Systems – SmartPanel: Rare DIsease Diagnostics – Algorithm Competition – automate from MDs Notes

    14. Bio-IT World Personalized & Translational Medicine WINNER @MGH NeuroBank Patient-Centric Platform Clinical Research

    15. Bio-IT World IT Infrastructure- WINNER Celgene

    16. Bio-IT World Clinical & Health IT – WINNER TakedaPharmaceutical Nominated by Deloitte

    17. Bio-IT World Best Practices Awards – WINNER AstraZeneca, Nominated by Genedata IMED BioTech Unit

    18. Franklin Award goes to Desmond G. Higgins, PhD, Professor, Biochemistry, University College Dublin Conway Institute of Biomolecular & Biomedical Research

    19. @BenjaminFranklin and @JWBizzaro, Managing Director, .org Presented Award to @DesmondGHiggins

    20. Synopsis Day 1 Track 7 – 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center via

    21. or 2015 support clean sheet design create RQS for Samples Assign processes Track progres register Samples Register plates Aliquoting Storage Graphical register consumables

    22. $11Bil – $28Billion of in systems &J @VedantaBioscinces announced a collaboration approach for : , beneficial symbionts,

    23. clever architecture for NGS tp://vqt.bioteam.net – Variant Query Tool – Server-less

    24. @ChavaKimchiSarfaty based solely on calculated data do not correlate with engineered therapeutics – benefit from Codon Opt

    25. @LBSHealth how to create new THAI Gov’t need methods to increase and years of


Bio-IT World Announces 2018 Best Of Show Award Winners

Reporter: Aviva Lev-Ari, PhD, RN

Aviva Lev-Ari Retweeted Mary-Ann Moore

Aviva Lev-Ari added,

  1. Award-winning Science Writer; Columnist, New York Times; Author of She Has Her Mother’s Laugh, 2018) Up to 30 top contributed the largest to

  2. Plenary Keynote Presentation: Height and Intelligence: Exploring the Complexity and Controversy of Heredity

  3. 2018 BioIT AWARDS Judges’ Prize WINNER Alexion Pharmaceuticala nominated by EPAM Systems – SmartPanel: Rare DIsease Diagnostics – Algorithm Competition – automate from MDs Notes

  4. Bio-IT World Personalized & Translational Medicine WINNER @MGH NeuroBank Patient-Centric Platform Clinical Research

  5. Bio-IT World IT OINfrastructure- WINNER Celgene

  6. Bio-IT World Clinical & Health IT – WINNER TakedaPharmaceutical Nominated by Deloitte

  7. Bio-IT World Best Practices Awards – WINNER AstraZeneca, Nominated by Genedata IMED BioTech Unit

  8. Franklin Award goes to Desmond G. Higgins, PhD, Professor, Biochemistry, University College Dublin Conway Institute of Biomolecular & Biomedical Research

  9. @BenjaminFranklin and @JWBizzaro, Managing Director, .org Presented Award to @DesmondGHiggins

May 16, 2018 | BOSTON—Bio-IT World announced the 2018 winners of the Best of Show Awards Program to a packed audience at the Bio-IT World Conference & Expo. The awards program recognizes the best of the innovative product solutions for the life sciences industry on display at the Bio-IT World conference in Boston.

“It’s always a treat to explore what’s new in our industry,” said Bio-IT World Editor, Allison Proffitt. “The innovation on display by Bio-IT World exhibitors never disappoints, and we are excited to shine a spotlight on the best life sciences has to offer.”

The Best of Show program relies on a panel of expert judges from academia and industry who screen eligible new products and hear presentations from a list of finalists on site. This year our judges considered 46 new products and viewed presentations on site from 18 finalists.

The judges named winners in six categories this year: Data Integration & Management; Analysis & Data Computing; Genomic Data Services; Data Visualization & Exploration; Storage Infrastructure & Hardware; and the Judges’ Prize. Attendees also voted on the People’s Choice Award, selecting products that they believe measurably improve workflow or capacity, enabling better research.

The 2018 judging panel included Joe Cerro, BostonCIO; Chris Dwan, Bridgeplate; Richard Holland, New Forest Ventures; Eleanor Howe, Diamond Age Data Science; Phillips Kuhl, Cambridge Healthtech Institute; Steve Marshall, Marshall Data Solutions; Michael Miller, Genentech; Art Morales, Analgesic Solutions; Nanguneri Nirmala, Tufts University School of Medicine; Alexander Sherman, Massachusetts General Hospital; Subi Subramanian, Vertex Pharmaceuticals; Bill Van Etten, BioTeam; and Proffitt.

 

2018 Bio-IT World Best of Show Winners

 

People’s Choice

OnRamp BioInformatics, Inc.
ROSALIND
onramp.bio/meet-rosalind

OnRamp BioInformatics provides ROSALIND™, the first-ever genomics analysis platform specifically designed for life science researchers to analyze and interpret datasets, while freeing up more time for bioinformaticians. Named in honor of pioneering researcher Rosalind Franklin, who made a major contribution to the discovery of the double-helix structure of DNA with her famous photograph 51, OnRamp’s ROSALIND platform aims to simplify the practice of genomic data interpretation.

ROSALIND puts the researcher into the driver’s seat of data analysis and democratizes bioinformatics by broadly expanding access to genomic and proteomic technologies for cancer research, precision medicine and sustainable agriculture.

While many open-source tools remain the lifeline of genomic analysis, a simplified and innovative user experience for the biologist can empower them to run their own analyses, while utilizing these tools without the need for typing any command-line instructions.

ROSALIND is powered in partnership with Google Cloud and features scalable compute power and economical cloud-based storage. ROSALIND is a swarming docker-based genomic analysis solution incorporating the industry’s most trusted open-source tools and algorithms, with an angular front-end and secure RESTful API. ROSALIND is also deployable on-premise.

We believe that by empowering biologists with an intuitive and comprehensive platform to explore their data and collaborate with colleagues and bioinformaticians, we can help accelerate our industry and the widespread adoption of genomic technologies by dramatically lowering costs, taking out complexity and, ultimately, putting more focus back on what to do with results, not how to get to them.

 

Data Integration & Management

The Hyve BV
RADAR-base
radar-cns.org

Developed in the framework of the IMI RADAR-CNS project, RADAR-base is an open source platform designed to securely collect, store and share readings from wearable devices and smartphone sensors to enable remote monitoring. The RADAR-base platform consists of three major categories of components:

Data ingestion: Recognizing and registering data-sources (including smartphones and wearable devices), collecting the data via a direct Bluetooth connection or through a 3rd party API and streaming in near real time to the server (green box in the figure). Using Apache Kafka, the collected data is streamed to dedicated topics in real-time where the data is optimally schematized using Apache Avro;

Data storage and management: Consists of two centralized storage systems behind an authorized security layer. A cold-storage based on HDFS that is scalable and fault-tolerant focusing on storing large volumes of high frequency raw-data, and a hot-storage based on MongoDB storing aggregated data to provide a near real-time overview of the raw-data. (blue box in the figure);

Data sharing: Visualizing aggregated data in a live dashboard and exporting raw data for further analyses in various formats including AVRO, JSON and CSV (yellow box in the figure).

The platform is highly secured by a centralized management system of users and their authorities, participants, allowed devices and their specifications. RADAR-Base platform is distributed as Docker containers with associated scripts and configuration files to enable easy installation.

 

Analysis & Data Computing

Sinequa
Sinequa ES v10
sinequa.com

The Sinequa Cognitive Search and Analytics platform handles all structured and unstructured data sources and uses Natural Language Processing (NLP), statistical analysis and Machine Learning (ML) in order to create an enriched “Logical Data Warehouse” (LDW). This LDW is optimized for performance in delivering rapid responses to users’ information needs. Users can ask questions in their native language or ask that relevant information be “pushed” to them in a timely fashion when it emerges.

More than 180 connectors ready for use “out of the box” make the process of connecting multiple data sources fast and seamless. Company and industry-specific dictionaries and ontologies can be easily integrated, putting specific knowledge “under the hood” of the Sinequa platform, making it an intelligent partner for anyone in search of relevant subject information.

 

Genomic Data Services

Diploid
Moon 1.0
diploid.com/moon

Moon is the first software to autonomously diagnose rare diseases from WES/WGS data. By applying AI to the domain of rare disease diagnostics, Moon brings speed and scalability to the genome interpretation process.

The software only requires the patient’s gender, age of onset and his/her symptoms – in addition to the genetic data. Moon then goes from whole genome variant data (VCF) to pinpointing the causal variant in less than 5 minutes.

The software highlights one or a few variants that could explain the patient’s phenotype. For every variant, Moon displays an extensive list of annotations that it mined from the literature, allowing geneticists to easily verify decisions from the AI algorithms. Moon’s speed does not only save a lot of time and money, it also saves lives: Moon has already proven its utility in the NICU at Rady Children’s Hospital (San Diego): https://goo.gl/7TDrQD.

Unfortunately, about 50% of rare disease patients remain undiagnosed, even after whole genome sequencing and expert interpretation. Most hospitals don’t have the resources to keep analyzing negative cases even though new correlations between genes and disorders are published every day. Moon changes all this: as the software autonomously mines the literature and analyses samples, it can reanalyze older, negative cases in the background. Only when new information that might lead to a diagnosis becomes available, the assigned geneticist is notified. That way, hospitals can frequently reanalyze thousands of cases with minimal labor, providing a perspective to undiagnosed patients.

 

Data Visualization & Exploration

Nanome
NanoPro
nanome.ai/

Nanome is helping to improve the drug discovery process through intuitive virtual reality interfaces. They developed applications for experimentation, collaboration, and learning at the nano-scale leveraging leading VR hardware like the Oculus Rift and HTC Vive to create immersive virtual workspaces wherein users can visualize, design, and simulate molecules, proteins, and more. To try the next generation of tools for small molecule design and macromolecular exploration, stop by the Nanome Booth: #711.

There you’ll have the ability to:

  • Import molecular structures from a local machine or an online database such as RCSB or DrugBank.
  • – Manipulate molecular structures by literally grabbing, rotating, or enlarging the area of interest with their hands.
  • – Apply different representations to their selection of Atoms, Residues, Chains, or Proteins such as Stick, Wire, Ball & Stick, or Van der Waals.
  • – Measure distances and angles between atoms.
  • – Mutate amino acids and cycle through rotamer libraries.
  • – Design small molecules by building with any element from the periodic table.
  • – Minimize manipulated molecules to prevent clashes and provide a local energy minimum conformation.
  • – Duplicate or Split any selected area of your structure to modify or export independently.
  • – Export your molecular structures to PDB.
  • – Join a virtual reality session as a guest with or without virtual reality hardware.
  • – Present and collaborate in the same virtual environment with colleagues to demonstrate proposals or compare before and after results.

 

Storage Infrastructure & Hardware

PetaGene
PetaSuite Cloud Edition – Version 1.2
petagene.com

Launching at Bio-IT World 2018, PetaSuite Cloud Edition (CE) combines two innovations: (i) the ability for a user’s software tools and pipelines to seamlessly integrate with a wide variety of cloud platforms without modification, and (ii) significantly improved, high-performance, scalable PetaSuite genomic compression technology.

For example, users can now directly run, without modification, their custom BWA-mem, GATK, Python, Java, shell scripts, and other POSIX-based software/pipelines streaming directly to/from AWS, Google Cloud, Azure, and private cloud storage, as though they were local filestores. PetaSuite CE supports each platform’s object encryption during transfer and at rest. User applications can connect to multiple cloud platforms, buckets and regions as desired, transparently, and on demand, in user-mode, without needing to modify their pipelines, setup mounts, or have administrator privileges.

Whether running on bare-metal, in VMs, or within Docker containers, for public, private or hybrid cloud, PetaSuite CE enables organizations to unlock the power of distributed object storage seamlessly from their POSIX-compliant tools and pipelines.

PetaSuite CE is built from the ground-up for the extremely high performance streaming and random-access workloads demanded by genomics applications. The integrated, transparent PetaGene compression has been significantly improved to deliver even faster compression and greater reductions of up to 6x of both BAM and FASTQ.GZ files, enabling large costs savings in cloud storage and data transfer times. Moreover, PetaGene compression can also preserve the MD5 checksum of the original BAM or FASTQ.GZ file and not just the internal raw SAM/FASTQ data.

 

Judges’ Prize

Linguamatics
iScite 2.0
iscite.com

Linguamatics iScite, a Software-as-a-Service search application, puts the power of text analytics directly into scientists’ hands.

Award-winning Natural Language Processing
Researchers can extract and analyze relevant data to rapidly answer business-critical questions. iScite utilizes Linguamatics’ award-winning Natural Language Processing (NLP) based blend of analytical methods. By understanding the semantics and structure of text, iScite handles the variety of ways people express the same information, ensuring searches are comprehensive and accurate.

Easy to use on any device
iScite’s intuitive HTML interface includes a simple search box and auto-complete suggestions. The innovative answer-routing engine lets users answer simple or complex questions using puzzle-piece building blocks – simplifying access to powerful queries that extract concepts, relationships, numerical data such as drug dosages, mutations and more.

Get answers to questions, not just documents
Data sources include Linguamatics’ cloud-hosted content. MEDLINE, Clinical Trials.gov, FDA Drug Labels, PubMed Central, and Patent Abstracts are annotated with curated terminologies for diseases, drugs, genes and organizations. Scientists can answer questions such as:

  • What genes are involved in breast cancer?
  • What protocol designs have been used for immuno-oncology trials?
  • What are the adverse events for kinase inhibitors?

Actionable results
Results are presented in structured form, with bar chart facets for dynamic, visual results-filtering, a document viewer that highlights key terms and relationships, and relevant link-outs. Users can curate, save, and export their results.

iScite allows users across drug discovery and development to cut through the vast information landscape and discover the most valuable insights.

SOURCE

 

THURSDAY, MAY 17 | 8:00 – 9:45 AM

8:00 Organizer Remarks

Cindy Crowninshield, RDN, LDN, HHC, Senior Conference Director/Team Lead, Cambridge Healthtech Institute

 Kanda Software8:05 Awards Program Introduction

Alex Karpovsky, CEO, Kanda Software Inc.

8:10 Benjamin Franklin Awards and Laureate Presentation
J.W. Bizzaro, Managing Director, Bioinformatics.org 

Desmond G. Higgins, PhD, Professor, Biochemistry, University College Dublin Conway Institute of Biomolecular & Biomedical Research – FOR CONTRIBUTIONS to Open Access Softward for Genome Sequences FASTP, FASTN, FASTA, BLAST – development on word processors – Time O(L to the N) – & Seq – 2406 years to complete sequencing

Progressive Alignment: 1984 – 1988, Desmond G. Higgins and SHarp, 1988,1989

BEFORE WWW

  • 1984 Nucleotide Sequences – Part I – GenBank EMBL
  • Journal of Biological Chemistry
  • Condition of Publication in Journal – submit SEQUENCES in three copies before for the Nucleotide Sequences Book
  • Michael Ashbutner – The EBI – Open Access to Genome Sequences – Hixton Hall
  • EMBL – European Bioinformatics Institute
  • Dublin Conway Institute – Mainframe computer moving to PCs
  • PCs – Clustal1 – Clustal4, 1988, Paul Sharp, Dublin
  • 1992 – Interner distribution – Clustal V 1992: EMBL Heidelberg, Rainer Fuchs Alan Bleasby
  • Clustal W, Clustal X, 1994 – 2007
  • Clustal W and Clustal 2.0, 2007
  • Top 30 papers on ISI up to 2015: Citation is a measure of ACTIVITY not of IMPORTANCE
  • 2008 Plan: Start from scratch
  • Clustal Omega – Release 4/2011
  • http://ebi.ac.uk/Tools

 

8:35 Bio-IT World Best Practices Awards
Allison Proffitt, Editorial Director, Bio-IT World

8:50 Keynote Introduction

  • Fastest Lowest Cost of WGA in Fire Cloud —
  • Genomics Analytics GATK4 of Intel
  • 5X in 1/3 the Time
  • AI in Genomics with GATK4 – GREATER Accuracy and Performance – Tensorflow

Michael McManus, Principal Solution Architect, Sales Marketing Group, Intel Corporation

9:00 Plenary Keynote Presentation: Height and Intelligence: Exploring the Complexity and Controversy of Heredity

Carl Zimmer

Award-winning Science Writer; Columnist, New York Times; Author of She Has Her Mother’s Laugh (coming May 2018)

Heredity has long been one of the foundations of society–but also the justification for some of the worst crimes in history. It has only been in the past century that scientists have begun to work out some of its molecular details. But the mysteries and controversies over heredity have proved remarkably durable. In my talk, I’ll explore the history and current research into heredity of two traits–height and intelligence. They may seem at first to be polar opposites, but it turns out they actually share some remarkable similarities.

Carl Zimmer is the author of 13 books about science. His newest book is She Has Her Mother’s Laugh: The Power, Perversions, and Potential of Heredity. His column, “Matter,” appears each week in the New York Times. Zimmer’s writing has earned a number of awards, including the 2016 Stephen Jay Gould Prize, awarded by the Society for the Study of Evolution to recognize individuals whose sustained efforts have advanced public understanding of evolutionary science. In 2017, he won an Online Journalism Award for his series of articles in which he explored his genome. A professor adjunct at Yale University, Zimmer is a familiar voice on programs such as Radiolab. He lives in Connecticut with his wife Grace and their children, Charlotte and Veronica. He is, to his knowledge, the only writer after whom a species of tapeworm has been named.

  • Galton,
  • Herditary Genius: Laws and Consequences, 1869
  • Twins: Hereditary & the Environment: Monozygotic twins vs Dizygotic twins, and adopted twins into different families
  • Laron Syndrome – very low stature
  • Growth Hormone – AIP gene
  • Joel Hirschhorn, Broad Institute
  • 3290 – 2018 700,00 people
  • Jonathan Pitcher – Polygenic to Omnigenic
  • Average Women’s Height (cm): Canada 157.6 CM [163.9 in 2018 vs Barbas 152.1 {169.2 in 2018]
  • Eugenics, Henry Goddard (advocated Sterilization) studied feable minded childrenVineland Training School, NJ
  • Binet – Intelligence Test related to Age
  • Feable mindedness related to hereditery: Emma Wolverton – Case study in Inheritance Kallikak Family
  • Das Erbe, 1935
  • Ian Deary, Univ of Edinburgh, 90s Correlation between IQ and mental processes
  • Sniekers, et al, Natural Genetics 49.7 – 52 Genes tied to Human Intelligence NYT, 05/22/2017
  • Up to 30 top SNPs contributed the largest to IQ Scores
  • Ancestry.com – Million of Gemone Profiles
  • DNALand.com
  • Lower Iodine – lower IQ, added Iodine to water then crops pregnant women increase IQ by 16 points.
  • Height – complex: DIet weight more protein, healthier pregnancy

 

 

 

9:45 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced

9:45 Book Signing

She Has Her Mother’s Laugh
Carl Zimmer, Award-winning Science Writer and Columnist, New York Times


Vyasa Analytics Demos Deep Learning Software for Life Sciences at Bio-IT World 2018 – Vyasa’s booth (#632)

 

Reporter: Aviva Lev-Ari, PhD, RN

 

BOSTON – May 10, 2018 Vyasa Analytics, a provider of deep learning software and analytics for life sciences and healthcare organizations, today announces three pre-built deep learning analytics modules for its Cortex software at Bio-IT World Conference & Expo. Cortex enables the secure, scalable application of deep learning-based artificial intelligence (AI) analytics to enterprise data, identifying patterns, relationships and concepts across disparate data sources.

 

The new Neural Concept Recognition, Image Analytics and ChemVector analytics modules in Cortex enable life sciences organizations to quickly and easily apply deep learning analytics to large data streams of text, images and chemical structures. Like all deep learning analytical modules in Cortex’s library, these new modules allow users to ask complex questions of their data and use the answers to gain critical insights.

 

“Life sciences and healthcare organizations are using AI tools to advance research and development and deliver better patient care. Deep learning algorithms provide a set of powerful approaches that help us apply analytics more effectively and comprehensively across large scale data sources,” said Dr. Christopher Bouton, founder and CEO of Vyasa. “The idea of AI has been around for decades, but we are now experiencing a perfect storm of GPU-based computing power, deep learning algorithm advances and highly scalable data sources that enables paradigm-shifting machine learning and analytics capabilities.”

 

Vyasa will be demoing three deep learning analytics modules for Cortex at Bio-IT World 2018 in Boston from May 15 to 17, including:

 

  • Neural Concept Recognition. This module can be trained on text concepts (e.g. drugs, diseases, pathways, conditions, side effects, genes) in structured and unstructured data. Users can ask Cortex complex questions across large scale data sets, and discover unexpected relationships between concept types. Concept recognition analytics is applicable to a wide range of use cases from competitive intelligence, to drug repurposing and EHR analytics.

 

  • Life Sciences R&D Specialized Image Analytics. Deep learning enables novel, powerful forms of image analytics, capable of being trained to detect patterns and objects in large scale image data sources. With just a few clicks in Cortex, the user can connect large streams of image data and apply analytics to those sources. Vyasa has finely-tuned this analysis for life sciences images, and it is ideal for cell assay screening, drug manufacturing and post-market screening for counterfeit packaging and tablets.
  • ChemVector de novo Compound Design. This proprietary Cortex module applies deep learning to chemical structures. Users can drag and drop one or more SDF files containing SMILES strings into Cortex, and Cortex can identify and generate novel compounds that optimize critical variables such as log-p, molecular weight and synthetic viability. ChemVector can be used with a range of other chemistry-specific analytical modules also available in Cortex.

 

 

Dr. Bouton, Vyasa’s founder and CEO, received his BA in Neuroscience (Magna Cum Laude) from Amherst College in 1996 and his Ph.D. in Molecular Neurobiology from Johns Hopkins University in 2001. Previously Dr. Bouton was the CEO of Entagen a software company founded in 2008 that provided innovative Big Data products including Extera and TripleMap. Entagen’s technologies won numerous awards including the “Innovative Technology of the Year Award for Big Data” from the Massachusetts Technology Leadership Council in 2012 and Entagen was recognized as a Gartner “Cool Vendor” in the Life Sciences in 2013. Entagen was acquired by Thomson Reuters in 2013. Dr. Bouton is an author on over a dozen scientific papers and book chapters and his work has been covered in a number of industry news articles.

 

Visit Vyasa and demo Cortex at booth #632, and watch the explainer video at www.vyasa.com.

About Vyasa Analytics

Vyasa Analytics provides deep learning software and analytics for life sciences and healthcare organizations. Cortex is Vyasa’s secure, highly scalable software platform for collaborative knowledge discovery and data analytics. Using Vyasa’s proprietary Neural Concept Recognition technology, Cortex identifies trends and patterns across disparate data sources, empowering project teams to gain insights and drive better decision making. Learn more at www.vyasa.com.

 

 

Angela Zmyslinski
Account Executive
azmyslinski@matternow.com
Office – 401-330-2800

     

SOURCE

From: Angela Zmyslinski <azmyslinski@matternow.com>

Date: Thursday, May 10, 2018 at 2:39 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: Demo deep learning software for life sciences at Bio-IT World 2018